Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy

Chest

Volumn 127, Issue 4, 2005, Pages 1312-1326

  Busse, William ^a   Kraft, Monica ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Asthma; Cytokines; Eosinophils; Inflammation; Leukotriene receptor antagonists; Leukotrienes; Remodeling; Rhinitis

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; LEUKOTRIENE RECEPTOR; METHACHOLINE; MONTELUKAST; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; PRANLUKAST; ZAFIRLUKAST; AUTACOID; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE;

ALLERGIC RHINITIS; ASTHMA; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG MECHANISM; EOSINOPHIL; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOOTH MUSCLE CONTRACTION; ADULT; CHILD; DRUG ANTAGONISM; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; PERENNIAL RHINITIS; PHENOTYPE;

ADULT; CHILD; CYSTEINE; HUMANS; HYPERSENSITIVITY; INFLAMMATION MEDIATORS; LEUKOTRIENES; PHENOTYPE; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 19044376965     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.4.1312     Document Type: Review

References (116)

1. Lemanske RF Jr, Busse WW. Asthma. JAMA 1997; 278: 1855-1873
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 2002; 110:5141-5219
3. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute, 1997
4. Lierl MB. Allergy of the upper respiratory tract. In: Lawlor GJ, Fischer TJ, Adelman DC, eds. Manual of allergy and immunology. Boston, MA: Little, Brown and Company, 1995; 95-111
5. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:5147-5334
6. 4, and histamine in normal human subjects. Thorax 1984; 39:500-504
7. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157:5210-5213; discussion 5247-5218
8. 4: comparison of potency in canine trachea in vivo. Prostaglandins 1983; 25:237-243
9. Hamid Q, Tulic MK, Liu MC, et al. Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol 2003; 111:55-512; discussion S12-S17
10. Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119:1533-1546
11. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16:289-297
12. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16:304-309
13. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568-575
14. Lee E, Robertson T, Smith J, et al. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000; 161:1881-1886
15. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1:584-588
16. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146:104-108
17. 4 after exercise and attenuation of exercise-induced ronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52:1030-1035
18. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142:112-119
19. Pavord ID, Ward R, Woltmann G, et al. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999; 160:1905-1909
20. Macfarlane AJ, Dworski R, Sheller JR, et al. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000; 161:1553-1558
21. 4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 136:357-362
22. 1 receptor. Nature 1999; 399:789-793
23. Evans J, Figueroa DJ. Cloning and expression of leukotriene receptors. Clin Exp Allergy Rev 2001; 1:142-144
24. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163:226-233
25. Mellor EA, Maekawa A, Austen KF, et al. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 2001; 98:7964-7969
26. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002; 32:1007-1012
27. Barnes N, Wei LX, Reiss TF, et al. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 2001; 95:379-386
28. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997; 19:675-690
29. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213-1220
30. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52:523-527
31. Kemp JP, Minkwitz MC, Bonuccelli CM, et al. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Chest 1999; 115:336-342
32. Dockhorn RJ, Baumgartner RA, Leff JA, et al. Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 2000; 55:260-265
33. Zhang J, Yu C, Noonan G, et al. Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability. Clin Ther 2002; 24:574-582
34. Ishioka S, Hozawa S, Haruta Y, et al. Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids. Hiroshima J Med Sci 2000; 49:105-108
35. Obase Y, Shimoda T, Tomari S, et al. Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene- receptor antagonist: four-year follow-up study. Ann Allergy Asthma Immunol 2001; 87:43-47
36. Ferreira MB, Santos AS, Pregal AL, et al. Leukotriene receptor antagonists (montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris) 2001; 33:315-318
37. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130: 487-495
38. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847-854
39. Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003; 21:123-128
40. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001; 31:845-854
41. Riccioni G, Vecchia RD, D'Orazio N, et al. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm Pharmacol Ther 2003; 16:111-114
42. Carratu P, Morelli N, Freire AX, et al. Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma. Respiration 2003; 70:249-253
43. Yoshida S, Ishizaki Y, Shoji T, et al. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000; 30:1008-1014
44. Westbroek J, Pasma HR. Effects of 2 weeks of treatment with fluticasone propionate 100 meg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. Respir Med 2000; 94:112-118
45. Rorke S, Jennison S, Jeffs JA, et al. Role of cysteinyl leukotrienes in adenosine 5′-monophosphate induced bronchoconstriction in asthma. Thorax 2002; 57:323-327
46. Dempsey OJ, Wilson AM, Sims EJ, et al. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000; 117:950-953
47. Dempsey OJ, Fowler SJ, Wilson A, et al. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002; 122:151-159
48. 4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 1998; 81:43-49
49. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:177-183
50. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998; 102:935-942
51. Virchow JC, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578-585
52. Calhoun WJ, Lavins RJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157:1381-1389
53. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12-18
54. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999; 160:1862-1868
55. Price DR, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211-216
56. Lofdahl C-G, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319:87-90
57. Centanni S, Santus P, Casanova F, et al. Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data. Drugs Exp Clin Res 2000; 26:133-138
58. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279:1181-1186
59. Knorr R, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48
60. Pearlman DS, Lampl KL, Dowling PJ Jr, et al. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000; 22:732-747
61. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001; 138: 694-698
62. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001; 17:96-104
63. Ng DK, Law AK, Chau KW, et al. Use of montelukast in the treatment of early childhood wheezing from clinical experience with three cases. Respirology 2000; 5:389-392
64. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003; 167:379-383
65. Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49-54
66. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sI-CAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109:257-263
67. Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528-533
68. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152
69. Dahlen B, Roquet A, Inman MD, et al. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J Allergy Clin Immunol 2002; 109:789-793
70. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14_year-old children with asthma. J Pediatr 1998; 133:424-428
71. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999; 134:273-279
72. Peroni DG, Piacentini GL, Pietrobelli A, et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. Eur Respir J 2002; 20:104-107
73. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9-14
74. Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29:42-51
75. Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155:1856-1863
76. Hamilton A, Faiferman I, Stober P, et al. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998; 102:177-183
77. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol 2002; 109:794-799
78. Phipatanakul W, Eggleston PA, Conover-Walker MK, et al. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol 2000; 105:704-710
79. Corren J, Spector S, Fuller L, et al. Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. Ann Allergy Asthma Immunol 2001; 87:211-217
80. Piatti G, Ceriotti L, Cavallaro G, et al. Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacol Res 2003; 47:541-547
81. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88:592-600
82. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32:1020-1028
83. van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90:214-222
84. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88:592-600
85. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32:1020-1028
86. Greisner WA 3rd, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998; 19:185-188
87. Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980; 65:122-126
88. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003; 111:1171-1183
89. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992; 89:611-618
90. Braunstahl GJ, Overbeek SE, Kleinjan A, et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107:469-476
91. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161: 2051-2057
92. Braunstahl GJ, Overbeek SE, Fokkens WJ, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001; 164:858-865
93. Gaga M, Lambrou P, Papageorgiou N, et al. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 2000; 30:663-669
94. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001; 344:350-362
95. Kay AB. Allergy and allergic diseases: first of two parts. N Engl J Med 2001; 344:30-37
96. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 1999; 103:5382-5385
97. Braccioni F, Dorman SC, O'Byrne PM, et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol 2002; 110:96-101
98. 4 induces P-selectin and sialyl Lewis(x)-dependent alterations in leukocyte kinetics in vivo. Circ Res 1995; 77:879-887
99. 1 receptor-mediated mechanism. Clin Exp Allergy 2002; 32:745-750
100. 4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 2002; 109:676-680
101. 4) on motility of isolated normodense human eosinophils and neutrophils. Adv Exp Med Biol 1997; 400B:699-706
102. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 2002; 195:583-592
103. Wu AY, Chik SC, Chan AW, et al. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy 2003; 33:359-366
104. Tohda Y, Nakahara H, Kubo H, et al. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999; 29:1532-1536
105. 4 in human polymorphonuclear leukocytes. Blood 1999; 93:1399-1405
106. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160:1227-1231
107. Bratton DL, Lanz MJ, Miyazawa N, et al. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999; 28:402-407
108. Holgate ST, Peters-Golden M, Panettieri RA, et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:518-534; discussion S34-S16
109. Mechiche H, Naline E, Candenas L, et al. Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. Clin Exp Allergy 2003; 33:887-894
110. 1- and cysteinyl leukotriene 1-receptor blockade in human bronchus. Life Sci 2001; 68:2825-2834
111. Baud L, Perez J, Denis M, et al. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 1987; 138:1190-1195
112. Phan SH, McGarry BM, Loeffler KM, et al. Regulation of macrophage-derived fibroblast growth factor release by arachidonate metabolites. J Leukoc Biol 1987; 42:106-113
113. 4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro. Biochemistry 1988; 27:2846-2853
114. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002; 165:229-235
115. Henderson WR, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165:108-116
116. 4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998; 19:453-461